查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1847953

抗苗勒氏管激素检测市场：按产品、组件、应用和最终用户划分 - 全球预测（2025-2032 年）

Anti-Mullerian Hormone Test Market by Product, Component, Applications, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗苗勒氏管激素 (AMH) 检测市场将成长至 7.4442 亿美元，复合年增长率为 11.78%。

主要市场统计数据
基准年 2024 3.0541亿美元
预计年份：2025年 3.4021亿美元
预测年份：2032年 7.4442亿美元
复合年增长率 (%) 11.78%

透过综合考虑临床效用、获取途径和技术成熟度，建构现代抗苗勒氏管激素检测的格局。

本执行摘要全面回顾了抗苗勒氏管激素（AMH）检测，并整合了临床发展、技术创新和相关人员的期望。分析首先将AMH检测置于现代生殖医学的背景下，指出诊断准确性和以患者为中心的便利性正在再形成临床诊疗流程。诊断实验室、生育诊所、医院和研究机构越来越依赖AMH作为生育治疗方案製定、治疗分层和长期卵巢健康监测的关键生物标记。在此背景下，就地检验和自我测试剂套件作为补充性的便捷检测方式应运而生，以满足对更快检测週期和分散式检测的需求。

仪器、试剂和检测设计的技术成熟正在提高分析灵敏度和操作效率，使临床医生更有信心地根据结果采取行动。同时，支付方观点的转变和监管审查正在影响着检测方法的应用模式和采购标准。这些应用情况为后续章节提供了依据，阐明了关键概念，明确了主要相关人员，并概述了构成当代AMH检测格局的诊断、商业和监管因素。这为解读报告中的市场细分洞察、区域动态和策略建议提供了必要的背景。

确定将重塑AMH诊断在各个医疗管道的交付和应用方式的临床、技术和商业性驱动因素。

随着临床、技术和商业性因素的共同作用，AMH检测领域正在经历变革时期，重塑生殖诊断的提供和应用方式。在临床上，对个人化生育治疗方案和早期疗育的日益重视，提升了AMH作为纵向生物标记的地位，促使医疗机构将系列检测整合到诊疗流程中，而非依赖单次评估。这种向纵向监测的转变，刺激了对能够在不同检测环境下提供一致且可重复结果的检测方法的需求，从而推动了标准化和跨平台协调的进程。

在技​​术层面，桌上型仪器和可携式分析仪的普及正在使实验室工作流程分散化，而试剂和套件（包括客製化和标准化检测）的创新则在保证分析性能相当的前提下，实现了更快的周转速度。同时，即时检测和自测试剂套件的兴起，正在将检测范围扩展到传统临床环境之外，并支援远端医疗模式和患者自主管理。从商业性角度来看，竞争优势越来越依赖综合提案，包括分析准确性、易用性和整合式数位报告，以支援临床医生的决策和患者的参与。

监管预期也在同步演变，监管机构越来越重视检测方法的检验、临床相关性以及真实世界表现的证据。这种转变正在加速诊断试剂生产商、临床网路和数位医疗服务提供者之间的伙伴关係，并鼓励生产商优先考虑互通性、品管系统和上市后监测，以维持临床信心和产品应用。

评估近期关税政策变化如何重塑AMH诊断价值链的供应链策略、采购行为和营运韧性。

2025年的关税调整和贸易政策变化为支持AMH检测所需诊断设备、试剂和耗材的全球供应链带来了更多复杂性。进口关税的上涨导致先进的桌上型仪器、携带式分析仪和试剂组的到岸成本增加，给诊断实验室、生育诊所和医院的采购预算带来了压力。为此，一些製造商正在重新审视筹资策略，加快对替代供应商的资格认证，并探索关键零件的近岸外包和在岸外包方案，以确保供应连续性不受关税波动的影响。

依赖跨境供应专业生物试剂和检测组件的试剂盒和套件生产商也感受到了关税带来的累积成本压力。当关税增加投入成本时，除非企业透过流程优化、合约重新谈判和策略性定价调整来适应，否则利润空间将被压缩。如果生产或标籤变更需要在目标市场进行新的备案和验证，监管时间表会进一步加剧这些应对措施的复杂性。

从营运角度来看，终端用户面临设备购置和试剂成本上涨的困境，可能会推迟设备升级，或优先选择单次检测营运成本较低的高通量检测方式。同时，商业策略可能会更加註重配套服务协议、耗材订阅模式和本地化技术支持，以降低用户感知到的风险。关税政策的变化促使价值链上的相关人员提高供应链透明度、实现采购多元化并加强应急计画，以确保生殖健康所需的诊断能力得以持续。

了解产品模式、组件架构、临床应用和最终用户需求如何交织，共同决定AMH检测的机会和应用前景。

细分市场层面的动态揭示了不同的需求、营运要求和创新管道，这些因素共同指导产品设计、打入市场策略和临床应用。依产品类型划分，市场格局可分为就地检验和自测试剂套件，二者分别针对不同的应用场景。照护现场平台满足需要快速获得临床医生解读结果的临床环境需求，而自测试剂套件满足消费者自主检测和远端监测的需求。按组件划分，仪器和试剂/试剂套件构成了技术核心，其中仪器涵盖台式和可携式分析仪，兼顾了通量和分散性；试剂/试剂套件包括专为特定临床检验而设计的定制检测方法和针对广泛互通性优化的标准检测方法。

应用细分透过将应用分为卵巢储备评估、多卵巢症候群诊断和卵巢早衰预测三大类，进一步明确了临床优先事项。例如，卵巢储备评估将推动对具有可靠性和纵向可比性的检测法的需求，而多囊性卵巢症候群诊断和卵巢早衰预测可能需要整合其他荷尔蒙标记和临床演算法。从最终用户来看，诊断实验室、生育诊所、医院和研究机构的采购动机和工作流程限制各不相同。诊断实验室优先考虑标准化和高通量，生育诊所优先考虑临床决策支援和患者咨询，医院需要与更广泛的实验室资讯系统集成，而研究机构则优先考虑检测方法开发和检验的灵活性。

综上所述，这些细分领域突显了技术创新、监管证据和商业模式必须如何协调一致才能实现临床价值。製造商和服务供应商若能根据产品类型、组件配置、应用和最终用户环境的细微差别来客製化产品，将更有利于展现其临床效用和营运契合度。

检验了决定全球主要市场AMH检测普及程度的区域需求驱动因素、法律规范和基础设施现状。

区域动态揭示了不同的需求驱动因素、法规环境和基础设施考量，这些因素共同塑造了全部区域的采纳模式。在美洲，重点在于与现有生育管道的整合、报销谈判以及门诊照护现场平台的应用，这里的技术创新通常侧重于可扩展性，以支持高容量的生育项目和临床医生的分析。同时，欧洲、中东和非洲的监管和临床环境则呈现出异质性，跨境协调努力、不同的报销模式以及部分市场私人生育服务行业的扩张，都对产品参与策略和技术支援的本地化产生了影响。

亚太地区正迅速采用分散式检查方法，这主要得益于私部门对生育服务的大力投资以及消费者对诊断解决方案日益增长的需求。该地区多元化的管理体制和生产能力也为在地化生产伙伴关係和协作检验研究创造了机会。由于各地区在实验室基础设施、数位医疗整合以及支付方参与度方面存在差异，因此需要独特的价值提案，以协调全球技术标准与本地临床工作流程和采购实践。因此，策略性参与企业将结合强有力的临床证据和灵活的商业化模式，以应对区域差异，同时确保产品完整性和合规性。

揭示当今AMH诊断领导者的竞争重点、合作策略以及产品和服务整合方法。

AMH检测领域的竞争格局由成熟的诊断公司、专注于生殖健康的公司以及致力于去中心化和提升检测性能的敏捷创新者组成。主要企业正投资于跨平台相容性、提高分析准确性以及将检测结果与临床决策支援工具连接的整合彙报。与临床网路和学术中心的伙伴关係日益增多，旨在产生增强临床效用价值所需的真实世界证据；同时，与数位医疗供应商的策略合作也有助于提升病人参与和远端监测能力。

在组件层面，仪器製造商正专注于支援桌上型和可携式部署的模组化设计，而试剂和试剂套件开发商则优先考虑检测的稳健性和批次间一致性。提供客製化检测的公司可以透过客製化验证研究和与大型生育中心的共同开发契约来脱颖而出。同时，提供标准检测的公司则优先考虑易于实施和与各种仪器平台的互通性。服务模式也在不断发展。製造商正在扩展售后服务支援、培训计划和基本契约，以减少临床应用过程中的阻力。随着医疗机构寻求值得信赖的合作伙伴以实现可持续的诊断运营，那些兼具监管专业知识、供应链韧性和可扩展生产能力的公司很可能获得竞争优势。

诊断试剂生产商和临床领导者可采取切实可行的策略重点，以加速产品应用，同时增强供应链韧性和临床信心。

产业领导者应采取切实可行的策略，平衡创新、可及性和营运韧性，以满足不断变化的临床需求。首先，应优先考虑检测方法的标准化和跨平台协调，以确保长期可比性并增强临床医生的信心。其次，应实现采购管道多元化，并考虑建立区域性生产伙伴关係，以降低关税和供应链波动的影响。这些措施有助于提高供应的连续性，并缩短关键试剂和耗材的前置作业时间。

同步数位化至关重要。应将安全、以临床医生为导向的彙报整合到远端医疗工作流程中，以支援远距会诊和长期病患管理。商业模式应不断发展，包括配套服务协议、耗材订阅和基于绩效的合同，从而减少终端用户的采购摩擦。此外，应与生育诊所和学术机构建立合作研究伙伴关係，共同产生真实世界证据，并改善用于卵巢储备评估和多囊性卵巢症候群（PCOS）诊断等应用的临床演算法。最后，应投资于有针对性的监管策略和市场推广计划，以应对不同的区域性要求，同时保持产品品质和上市后监测，从而保障临床信心和产品的长期应用。

概述了一种混合方法研究途径，该方案结合了专家参与、文献综述和技术检验，以确保研究结果的可靠性和可操作性。

本综述的研究采用了混合方法，结合了主要相关人员的参与和二手证据的综合分析，以确保研究的深度和情境效度。主要资讯来源包括对临床医生、实验室主任、生育专家和采购负责人进行结构化访谈，以了解营运重点、检验预期和采购行为。这些访谈为定性编码提供了依据，从而揭示了与检测性能要求、部署限制和最终用户支援需求相关的反覆出现的主题。

二次分析纳入了同侪审查文献、监管指导文件和已发布的临床实践指南，以检验诊断概念并使分析标准与临床相关性保持一致。我们审查了行业技术文件和产品规格，以评估仪器架构、检测化学和互通性特性。我们透过贸易和监管公告评估了供应炼和政策发展情况，并从公开的技术报告和临床检验研究中获取了仪器和试剂选项的比较评估。这些资讯来源的交叉验证增强了结论的可靠性，并确保建议既反映了实际操作情况，也反映了临床需求。

将临床需求、技术能力和营运韧性联繫起来，为AMH诊断的策略决策提供指导，并得出最终结论。

总之，抗苗勒氏管激素检测领域正处于曲折点患者为中心的纵向诊断的临床需求与实现去中心化和提升分析性能的技术能力相融合。价值链上的相关人员必须应对受关税主导的供应链动态、各地区的不同要求以及不断变化的临床预期，这些因素共同决定了检测的普及模式。只有那些投资于检测标准化、供应链多元化和数位化整合的机构，才能在各个医疗环节提供可靠且便于临床医生使用的检测结果，从而取得成功。

此外，尊重个别需求的细分策略至关重要，该策略应涵盖照护现场和自测模式、设备和试剂架构、特定应用的分析标准以及多样化的终端用户工作流程。透过协调证据生成、商业化模式和营运弹性，企业可以更好地支持临床决策，扩大生殖健康诊断的覆盖范围，并最终改善患者预后。未来发展需要製造商、临床医生和医疗系统之间持续合作，将技术进步转化为可靠、可扩展的诊断解决方案。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 生育诊所采用即时抗穆氏管荷尔蒙检测平台的照护现场激增
  • 整合新一代定序和生物标记分析技术，可实现AMH检测结果的个人化解读。
  • 由于生育年龄延迟以及女性对怀孕的认识提高，对AMH检测的需求正在增加。
  • 快速微流体AMH检测技术的出现显着减少了样本用量和检测週期。
  • 扩大报销范围的措施改善了患者获得抗穆氏管荷尔蒙检测服务的机会。
  • 与诊断公司和远端医疗平台建立合作关係，以实现远端AMH监测解决方案
  • 新型体外诊断AMH检测方法核准，推动新兴地区市场扩张
  • 开发包含AMH标誌物的多重免疫检测盒，用于全面的生殖健康评估

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 依产品分類的抗苗勒氏管激素检测市场

  • POC测试
  • 自检套件

9. 依成分分類的抗苗勒氏管激素检测市场

  • 装置
    • 桌上型装置
    • 可携式分析仪
  • 试剂和套件
    • 客製化检测
    • 标准检测

第十章 依应用分類的抗苗勒氏管激素检测市场

  • 卵巢储备评估
  • 卵巢的诊断
  • 预测卵巢早衰

第十一章 依最终用户分類的抗苗勒氏管激素检测市场

  • 诊断实验室
  • 不孕不育诊所
  • 医院
  • 研究所

第十二章 抗苗勒氏管激素检测市场（依地区分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 依组别分類的抗苗勒氏管激素检测市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国抗苗勒氏管激素检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbexa Limited
    • Ansh Labs LLC
    • Athenese-Dx
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • bioMerieux SA
    • BioVendor-Laboratorni Medicina AS
    • Chengdu VACURE BIoTechnology Co., Ltd.
    • CTK BIoTech, Inc.
    • Cusabio Technology LLC
    • Danaher Corporation
    • Eagle Biosciences, Inc.
    • Elabscience Bionovation Inc.
    • Epitope Diagnostics, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Fujirebio Europe NV by HU Group Holdings, Inc.
    • Goldsite Diagnostics Inc.
    • Healthy Human Labs Limited（Vitall）
    • Kamiya Biomedical Company
    • LifeSpan BioSciences, Inc.
    • London Gynaecology Limited
    • Meridian Bioscience, Inc.
    • Monobind Inc.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Tosoh Corporation
    • Vitrosens BIoTechnology Co., Ltd.
Product Code: MRR-BC3400CDF7AF

The Anti-Mullerian Hormone Test Market is projected to grow by USD 744.42 million at a CAGR of 11.78% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 305.41 million
Estimated Year [2025] USD 340.21 million
Forecast Year [2032] USD 744.42 million
CAGR (%) 11.78%

Framing the contemporary Anti-Mullerian Hormone testing landscape by synthesizing clinical utility, access modalities, and technological maturation

This executive summary introduces a comprehensive examination of Anti-Mullerian Hormone testing, synthesizing clinical evolution, technological innovation, and stakeholder expectations into a cohesive narrative. The analysis begins by situating AMH testing within contemporary reproductive medicine, where diagnostic precision and patient-centric access are reshaping clinical pathways. Diagnostic laboratories, fertility clinics, hospitals, and research institutes increasingly rely on AMH as a critical biomarker to inform fertility planning, treatment stratification, and long-term ovarian health monitoring. Against this backdrop, both point-of-care testing and self-check kits are emerging as complementary access modalities that address demand for faster decision cycles and decentralized testing.

Technological maturation in instruments, reagents, and assay design has improved analytic sensitivity and operational throughput, enabling clinicians to act on results with greater confidence. Meanwhile, evolving payer perspectives and regulatory scrutiny are influencing adoption patterns and procurement criteria. This introduction frames the subsequent chapters by clarifying key concepts, identifying primary stakeholders, and outlining the diagnostic, commercial, and regulatory forces that together define the contemporary AMH testing landscape. It provides the context necessary for interpreting segmentation insights, regional dynamics, and strategic recommendations contained in the report.

Identifying the convergent clinical, technological, and commercial drivers that are restructuring how AMH diagnostics are delivered and adopted across care pathways

The AMH testing landscape is undergoing transformative shifts driven by converging clinical, technological, and commercial forces that are rewriting how reproductive diagnostics are delivered and consumed. Clinically, greater emphasis on personalized fertility planning and earlier intervention is elevating the role of AMH as a longitudinal biomarker, prompting providers to integrate serial testing into care pathways rather than relying on single-point assessments. This shift toward longitudinal monitoring has stimulated demand for assays that deliver consistent, reproducible results across different testing environments, creating pressure for standardization and cross-platform harmonization.

On the technology front, the diffusion of benchtop devices and portable analyzers is decentralizing laboratory workflows, while reagents and kit innovations-both customized assays and standard assays-are enabling faster turnaround with comparable analytic performance. Simultaneously, the rise of POC testing and self-check kits is expanding access beyond traditional clinical settings, supporting telehealth models and patient-managed care. From a commercial perspective, competitive differentiation increasingly rests on combined propositions of analytic accuracy, ease of use, and integrated digital reporting that supports clinician decision-making and patient engagement.

Regulatory expectations are also evolving in parallel, with authorities focusing on assay validation, clinical correlation, and real-world performance evidence. These shifts are accelerating partnerships among diagnostic manufacturers, clinical networks, and digital health providers, and they are prompting manufacturers to prioritize interoperability, quality-control systems, and post-market surveillance to sustain clinical trust and adoption.

Assessing how recent tariff developments are reshaping supply chain strategies, procurement behavior, and operational resilience across the AMH diagnostic value chain

Tariff adjustments and trade policy changes in 2025 have introduced additional complexity into global supply chains that support diagnostic instruments, reagents, and consumables integral to AMH testing. Increased import duties can translate into higher landed costs for sophisticated benchtop devices, portable analyzers, and reagent kits, exerting pressure on procurement budgets in diagnostic laboratories, fertility clinics, and hospitals. In response, some manufacturers are reassessing sourcing strategies, accelerating qualification of alternative suppliers, and exploring nearshoring or onshoring options for critical components to shield supply continuity from tariff volatility.

The cumulative effect of tariff-driven cost pressures also extends to reagent and kit manufacturers who rely on cross-border supply of specialized biological reagents and assay components. Where tariffs elevate input costs, there is potential for margin compression unless firms adapt through process optimization, contract renegotiation, or strategic pricing adjustments. Regulatory timelines can further complicate these responses when modifications to manufacturing or labeling require renewed submissions or validations in target markets.

From an operational standpoint, end users facing higher equipment acquisition or reagent costs may defer upgrades or prioritize high-throughput testing modalities that offer lower per-test operational expense. In parallel, commercial strategies are likely to emphasize bundled service agreements, consumable subscription models, and localized technical support to mitigate perceived risk. Ultimately, tariff developments are prompting stakeholders across the value chain to increase supply chain transparency, diversify sourcing, and fortify contingency planning to preserve access to diagnostic capabilities critical to reproductive care.

Uncovering how product modalities, component architectures, clinical applications, and end-user needs interplay to define opportunity and adoption in AMH testing

Segment-level dynamics reveal differentiated demand, operational requirements, and innovation pathways that inform product design, go-to-market strategies, and clinical adoption. Based on product, the landscape distinguishes between point-of-care testing and self-check kits, each targeting distinct use cases: point-of-care platforms cater to clinical settings seeking rapid, clinician-interpreted results, while self-check kits address consumer empowerment and remote monitoring needs. Based on component, instruments and reagents & kits define the technical backbone, where instruments span benchtop devices and portable analyzers that balance throughput and decentralization, and reagents and kits include customized assays designed for niche clinical validation alongside standard assays optimized for broad interoperability.

Application segmentation further clarifies clinical priorities by grouping use into ovarian reserve assessment, polycystic ovary syndrome diagnosis, and premature ovarian failure prediction, each of which imposes unique analytical sensitivity and reporting requirements. For example, ovarian reserve assessment drives demand for assays with reliable longitudinal comparability, whereas PCOS diagnosis and premature ovarian failure prediction may require integration with additional hormonal markers and clinical algorithms. Based on end user, diagnostic laboratories, fertility clinics, hospitals, and research institutes present varied purchasing rationales and workflow constraints; diagnostic laboratories emphasize standardization and throughput, fertility clinics focus on clinical decision support and patient counseling, hospitals require integration with broader laboratory information systems, and research institutes prioritize flexibility for assay development and validation.

Collectively, these segmentation lenses expose where innovation, regulatory evidence, and commercial models must align to capture clinical value. Manufacturers and service providers that tailor offerings to the nuanced requirements across product types, component configurations, applications, and end-user contexts will be better positioned to demonstrate clinical utility and operational fit.

Examining distinct regional demand drivers, regulatory frameworks, and infrastructure realities that determine AMH testing adoption across leading global markets

Regional dynamics display distinct demand drivers, regulatory environments, and infrastructure considerations that shape adoption patterns across key geographies. In the Americas, the emphasis is on integration with established fertility care pathways, reimbursement negotiation, and the adoption of point-of-care platforms in outpatient settings; innovation here often focuses on scalability and clinician-facing analytics that support high-volume fertility programs. Meanwhile, the Europe, Middle East & Africa region presents a heterogeneous regulatory and clinical landscape where cross-border harmonization efforts, varying reimbursement models, and an expanding private fertility services sector in select markets influence product entry strategies and localization of technical support.

Asia-Pacific exhibits rapid adoption of decentralized testing modalities, buoyed by strong private-sector investment in fertility services and a growing appetite for consumer-facing diagnostic solutions. The region's diverse regulatory regimes and manufacturing capacity also create opportunities for localized production partnerships and collaborative validation studies. Across all regions, differences in laboratory infrastructure, digital health integration, and payer engagement necessitate tailored value propositions that reconcile global technical standards with local clinical workflows and procurement practices. Strategic entrants will therefore combine robust clinical evidence and flexible commercialization models to navigate regional nuances while maintaining product integrity and regulatory compliance.

Highlighting competitive priorities, collaboration strategies, and product-service integration approaches that differentiate leaders in AMH diagnostics today

Competitive dynamics in the AMH testing space reflect a mix of established diagnostics companies, specialized reproductive health firms, and agile innovators focused on decentralization and assay performance. Key players are investing in cross-platform compatibility, enhanced analytical precision, and integrated reporting that links laboratory results with clinical decision support tools. Partnerships with clinical networks and academic centers are increasingly used to generate the real-world evidence necessary to strengthen clinical utility claims, while strategic collaborations with digital health vendors facilitate patient engagement and remote monitoring capabilities.

At the component level, instrument manufacturers concentrate on modular designs that support both benchtop and portable deployments, whereas reagent and kit developers prioritize assay robustness and lot-to-lot consistency. Firms offering customized assays can differentiate through tailored validation studies and co-development agreements with large fertility centers, while providers of standard assays emphasize ease of adoption and interoperability with diverse instrument platforms. Service models are also evolving: manufacturers are expanding after-sales support, training programs, and performance-based contracting to reduce friction during clinical adoption. Companies that integrate regulatory expertise, supply chain resilience, and scalable manufacturing will hold competitive advantages as institutions seek reliable partners for sustained diagnostic operations.

Actionable strategic priorities for diagnostic manufacturers and clinical leaders to accelerate adoption while enhancing supply chain resilience and clinical trust

Industry leaders should pursue actionable strategies that balance innovation, access, and operational resilience to capitalize on evolving clinical needs. First, prioritize assay standardization and cross-platform harmonization to ensure longitudinal comparability and clinician confidence; investing in multicenter validation studies and alignment with laboratory quality frameworks will accelerate clinical acceptance. Next, diversify sourcing and consider regional manufacturing partnerships to mitigate tariff and supply chain volatility; such moves improve continuity of supply and can shorten lead times for critical reagents and consumables.

Concurrent digital enablement is essential: integrate secure, clinician-oriented reporting with telehealth workflows to support remote consultations and longitudinal patient management. Commercial models should evolve to include bundled service agreements, consumables subscriptions, and outcome-linked arrangements that reduce end-user procurement friction. Additionally, cultivate collaborative research alliances with fertility clinics and academic institutions to co-generate real-world evidence and refine clinical algorithms for applications such as ovarian reserve assessment and PCOS diagnosis. Finally, invest in targeted regulatory strategy and market access planning to navigate heterogeneous regional requirements while maintaining product quality and post-market surveillance, thereby protecting clinical trust and long-term adoption.

Outlining a mixed-methods research approach combining expert engagement, literature synthesis, and technical validation to ensure robust, actionable insights

The research underpinning this summary employed a mixed-methods approach combining primary stakeholder engagement and secondary evidence synthesis to ensure depth and contextual relevance. Primary inputs included structured interviews with clinicians, laboratory directors, fertility specialists, and procurement leaders to capture operational priorities, validation expectations, and purchasing behaviors. These discussions informed qualitative coding to surface recurring themes related to assay performance requirements, deployment constraints, and end-user support needs.

Secondary analysis incorporated peer-reviewed literature, regulatory guidance documents, and published clinical practice guidelines to validate diagnostic concepts and align analytical criteria with clinical relevance. Industry technical documentation and product specifications were reviewed to assess device architectures, assay chemistries, and interoperability features. Supply chain and policy developments were evaluated through trade and regulatory notices, while comparative assessments of instrumentation and reagent options were derived from publicly available technical reports and clinical validation studies. Triangulation across these sources strengthened the robustness of insights and ensured recommendations reflect both operational realities and clinical imperatives.

Concluding synthesis that connects clinical demand, technological capability, and operational resilience to guide strategic decisions in AMH diagnostics

In conclusion, the Anti-Mullerian Hormone testing landscape is at an inflection point where clinical demand for longitudinal, patient-centered diagnostics converges with technological capabilities that enable decentralization and improved analytic performance. Stakeholders across the value chain must navigate tariff-driven supply chain dynamics, heterogeneous regional requirements, and evolving clinical expectations that collectively determine adoption patterns. Success will favor organizations that invest in assay standardization, supply chain diversification, and digital integration to deliver reliable, clinician-usable results across care settings.

Moreover, segmentation-informed strategies that respect the distinct needs of point-of-care and self-check modalities, instrument and reagent architectures, application-specific analytical criteria, and diverse end-user workflows will be essential. By aligning evidence generation, commercialization models, and operational resilience, firms can better support clinical decision-making, expand access to reproductive health diagnostics, and ultimately improve patient outcomes. The path forward requires sustained collaboration among manufacturers, clinicians, and health systems to translate technical advances into dependable, scalable diagnostic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in adoption of point-of-care anti-Mullerian hormone testing platforms across fertility clinics
  • 5.2. Integration of next-generation sequencing and biomarker analytics for personalized AMH test interpretation
  • 5.3. Rising demand for AMH testing driven by delayed childbearing and increasing fertility awareness among women
  • 5.4. Emergence of microfluidics-based rapid AMH assays reducing sample volumes and turnaround times significantly
  • 5.5. Expansion of insurance reimbursement policies enhancing patient access to anti-Mullerian hormone testing services
  • 5.6. Partnerships between diagnostics companies and telehealth platforms enabling remote AMH monitoring solutions
  • 5.7. Regulatory approvals for novel in vitro diagnostic AMH assays fueling market expansion in emerging regions
  • 5.8. Development of multiplex immunoassay panels incorporating AMH markers for comprehensive reproductive health profiling

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Mullerian Hormone Test Market, by Product

  • 8.1. POC Testing
  • 8.2. Self-check Kits

9. Anti-Mullerian Hormone Test Market, by Component

  • 9.1. Instruments
    • 9.1.1. Benchtop Devices
    • 9.1.2. Portable Analyzers
  • 9.2. Reagents & Kits
    • 9.2.1. Customized Assays
    • 9.2.2. Standard Assays

10. Anti-Mullerian Hormone Test Market, by Applications

  • 10.1. Ovarian Reserve Assessment
  • 10.2. Polycystic Ovary Syndrome Diagnosis
  • 10.3. Premature Ovarian Failure Prediction

11. Anti-Mullerian Hormone Test Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Fertility Clinics
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Anti-Mullerian Hormone Test Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-Mullerian Hormone Test Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-Mullerian Hormone Test Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbexa Limited
    • 15.3.2. Ansh Labs LLC
    • 15.3.3. Athenese-Dx
    • 15.3.4. Bio-Rad Laboratories, Inc.
    • 15.3.5. Bio-Techne Corporation
    • 15.3.6. bioMerieux S.A.
    • 15.3.7. BioVendor - Laboratorni Medicina A.S.
    • 15.3.8. Chengdu VACURE Biotechnology Co., Ltd.
    • 15.3.9. CTK Biotech, Inc.
    • 15.3.10. Cusabio Technology LLC
    • 15.3.11. Danaher Corporation
    • 15.3.12. Eagle Biosciences, Inc.
    • 15.3.13. Elabscience Bionovation Inc.
    • 15.3.14. Epitope Diagnostics, Inc.
    • 15.3.15. F. Hoffmann-La Roche Ltd.
    • 15.3.16. Fujirebio Europe N.V. by H.U. Group Holdings, Inc.
    • 15.3.17. Goldsite Diagnostics Inc.
    • 15.3.18. Healthy Human Labs Limited (Vitall)
    • 15.3.19. Kamiya Biomedical Company
    • 15.3.20. LifeSpan BioSciences, Inc.
    • 15.3.21. London Gynaecology Limited
    • 15.3.22. Meridian Bioscience, Inc.
    • 15.3.23. Monobind Inc.
    • 15.3.24. Siemens Healthineers AG
    • 15.3.25. Thermo Fisher Scientific Inc.
    • 15.3.26. Tosoh Corporation
    • 15.3.27. Vitrosens Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTI-MULLERIAN HORMONE TEST MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTI-MULLERIAN HORMONE TEST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-MULLERIAN HORMONE TEST MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SELF-CHECK KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHTOP DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CUSTOMIZED ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STANDARD ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN RESERVE ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PREMATURE OVARIAN FAILURE PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 240. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 241. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 242. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 243. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 244. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 245. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 246. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 247. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 248. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 249. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. GCC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 276. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 282. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 283. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 284. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 285. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 286. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 287. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 288. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 289. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 290. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 291. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. G7 ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 296. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 297. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 298. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 299. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 300. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 301. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 302. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 303. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 304. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 305. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. NATO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COMPONENT, 2025-203